12:00 AM
 | 
Feb 16, 2015
 |  BC Week In Review  |  Clinical News  |  Regulatory

Scenesse afamelanotide regulatory update

In December, the European Commission approved under exceptional conditions Scenesse afamelanotide from Clinuvel to prevent phototoxicity in patients with erythropoietic protoporphyria (EPP), a severe genetic disorder causing absolute ultraviolet radiation and light intolerance in the...

Read the full 154 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >